Management of Cardiac Toxicity Induced by Chemotherapy

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

(2020) G. Curigliano et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer

(2020) Noam Pondé et al.   EUROPEAN JOURNAL OF CANCER

Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines

(2020) Rebeca Mata Caballero et al.   Cardiology Journal

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

(2020) Kelly D. Getz et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS‐ONE trial

(2020) Jennifer M.T.A. Meessen et al.   ESC Heart Failure

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer

(2019) Maya Guglin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

(2019) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions

(2019) Stephen Kaptoge et al.   Lancet Global Health

Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events

(2018) Matthias Pinter et al.   CLINICAL CANCER RESEARCH

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

(2018) Daniela Cardinale et al.   EUROPEAN JOURNAL OF CANCER

Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling

(2018) Peter Reichardt et al.   Future Oncology

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

(2018) Mônica Samuel Avila et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Integration of Cancer Survivorship Care and Primary Care Practice

(2017) Emily S. Tonorezos et al.   JAMA Internal Medicine

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

Vascular Complications of Cancer Chemotherapy

(2016) Alan C. Cameron et al.   CANADIAN JOURNAL OF CARDIOLOGY

The Cardio-oncology Program: A Multidisciplinary Approach to the Care of Cancer Patients With Cardiovascular Disease

(2016) Sarah Parent et al.   CANADIAN JOURNAL OF CARDIOLOGY

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

(2016) Geeta Gulati et al.   EUROPEAN HEART JOURNAL

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404

(2016) Barbara L. Asselin et al.   JOURNAL OF CLINICAL ONCOLOGY

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Mohammad H Forouzanfar et al.   LANCET

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)

(2016) Sai-Hong Ignatius Ou et al.   Cancer Medicine

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

(2016) Lucie Heinzerling et al.   Journal for ImmunoTherapy of Cancer

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

(2015) D. Cardinale et al.   CIRCULATION

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation

(2015) Gabriele D’Uva et al.   NATURE CELL BIOLOGY

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

(2014) P Ghatalia et al.   BRITISH JOURNAL OF CANCER

Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials

(2014) Wei-Xiang Qi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Protective effects of spironolactone against anthracycline-induced cardiomyopathy

(2014) Mahmut Akpek et al.   EUROPEAN JOURNAL OF HEART FAILURE

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives

(2014) Monica Lamberti et al.   TOXICOLOGY LETTERS

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Cardiac toxicity in cancer survivors

(2013) Daniel J. Lenihan et al.   CANCER

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies

(2013) Xavier Bosch et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2013) S. M. Swain et al.   ONCOLOGIST

Risk-Based Health Care, the Cancer Survivor, the Oncologist, and the Primary Care Physician

(2013) Mary S. McCabe et al.   SEMINARS IN ONCOLOGY

Operationalizing the One Health approach: the global governance challenges

(2012) K. Lee et al.   HEALTH POLICY AND PLANNING

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure

(2012) Rodrigo Cardoso Santos et al.   Revista da Associacao Medica Brasileira

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis

(2011) Russell A. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review

(2010) Linda Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies

(2010) Geoffrey J. Yoon et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anthracycline-Induced Cardiomyopathy

(2010) Daniela Cardinale et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY